The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5814-5818

  Lacroix, Céline ^a   George, Shyla ^b   Leyssen, Pieter ^a   Hilgenfeld, Rolf ^b   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3C PROTEASE; AMINO ACID; ANTIVIRUS AGENT; CYTOPROTECTIVE AGENT; PEPTIDOMIMETIC AGENT; PLECONARIL; PROTEINASE; PROTEINASE INHIBITOR; RUPINTRIVIR; SG 85; UNCLASSIFIED DRUG; VIRUS ENZYME; 2 PYRROLIDONE DERIVATIVE; ISOXAZOLE DERIVATIVE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; EC50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVERSE GENETICS; RHINOVIRUS; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENTEROVIRUS; ENZYMOLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENTEROVIRUS; ISOXAZOLES; PROTEASE INHIBITORS; PYRROLIDINONES; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84940944425     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00534-15     Document Type: Article

References (22)

1. Jacobs SE, Lamson DM, St GK, Walsh TJ 2013. Human rhinoviruses. Clin Microbiol Rev 26:135-162. http://dx.doi.org/10.1128/CMR.00077-12.
2. Palmenberg A, Gern J. 2015. Classification and evolution of human rhinoviruses. Methods Mol Biol 1221:1-10. http://dx.doi.org/10.1007/978-1-4939-1571-2-1.
3. Gern JE, Galagan DM, Jarjour NN, Dick EC, Busse WW 1997. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am J Respir Crit Care Med 155:1159-1161. http://dx.doi.org/10.1164/ajrccm.155.3.9117003.
4. Gern JE. 2015. How rhinovirus infections cause exacerbations of asthma. Clin Exp Allergy 45:32-42. http://dx.doi.org/10.1111/cea.12428.
5. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, Aniscenko J, Laza-Stanca V, Edwards MR, Slater L, Papi A, Stanciu LA, Kon OM, Johnson M, Johnston SL. 2011. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 183:734-742. http://dx.doi.org/10.1164/rccm.201006-0833OC.
6. Thibaut HJ, De Palma AM, Neyts J. 2012. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol 83: 185-192. http://dx.doi.org/10.1016/j.bcp.2011.08.016.
7. Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW, III, Matthews DA, Patick AK. 2005. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 49:619-626. http://dx.doi.org/10.1128/AAC.49.2.619-626.2005.
8. Matthews DA, Smith WW, Ferre RA, Condon B, Budahazi G, Sisson W, Villafranca JE, Janson CA, McElroy HE, Gribskov CL, Worland S. 1994. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 77:761-771. http://dx.doi.org/10.1016/0092-8674(94)90059-0.
9. Leong LE, Walker PA, Porter AG 1993. Human rhinovirus-14 protease 3C (3Cpro) binds specifically to the 5'-noncoding region of the viral RNA. Evidence that 3Cpro has different domains for the RNA binding and proteolytic activities. J Biol Chem 268:25735-25739.
10. Walker EJ, Younessi P, Fulcher AJ, McCuaig R, Thomas BJ, Bardin PG, Jans DA, Ghildyal R. 2013. Rhinovirus 3C protease facilitates specific nucleoporin cleavage and mislocalisation of nuclear proteins in infected host cells. PLoS One 8:e71316. http://dx.doi.org/10.1371/journal.pone.0071316.
11. Malcolm BA. 1995. The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Protein Sci 4:1439-1445. http://dx.doi.org/10.1002/pro.5560040801.
12. Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW, III, Ferre RA, Brown EL, Binford SL, Harr JE, DeLisle DM, Worland ST. 1998. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J Med Chem 41:2806-2818.
13. Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Meador JW, III, Ferre RA, Worland ST. 1999. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem 42:1203-1212.
14. Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW, III, Ferre RA, Harr JE, Kosa MB, Worland ST. 1999. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem 42:1213-1224.
15. Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 43:2444-2450.
16. Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, Patick AK, Smith GJ, III, Zalman LS. 2003. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 47:3907-3916. http://dx.doi.org/10.1128/AAC.47.12.3907-3916.2003.
17. Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ, III, Zalman LS, Burns-Naas LA, Tran JQ. 2005. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 49:2267-2275. http://dx.doi.org/10.1128/AAC.49.6.2267-2275.2005.
18. Tan J, George S, Kusov Y, Perbandt M, Anemuller S, Mesters JR, Norder H, Coutard B, Lacroix C, Leyssen P, Neyts J, Hilgenfeld R. 2013. 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol 87:4339-4351. http://dx.doi.org/10.1128/JVI.01123-12.
19. Tijsma A, Franco D, Tucker S, Hilgenfeld R, Froeyen M, Leyssen P, Neyts J. 2014. The capsid binder vapendavir and novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother 58:6990-6992. http://dx.doi.org/10.1128/AAC.03328-14.
20. Lacroix C, Querol-Audi J, Roche M, Franco D, Froeyen M, Guerra P, Terme T, Vanelle P, Verdaguer N, Neyts J, Leyssen P. 2014. A novel benzonitrile analogue inhibits rhinovirus replication. J Antimicrob Chemother 69:2723-2732. http://dx.doi.org/10.1093/jac/dku200.
21. Binford SL, Weady PT, Maldonado F, Brothers MA, Matthews DA, Patick AK 2007. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 51: 4366-4373. http://dx.doi.org/10.1128/AAC.00905-07.
22. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LA, Hendrickson T, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci U S A 96:11000-11007. http://dx.doi.org/10.1073/pnas.96.20.11000.